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ㅋ
Achalasia is an esophageal motility disorder of unknown cause, characterized by aperistalsis of the esophageal body and im-
paired lower esophageal sphincter relaxation. Patients present at all ages, primarily with dysphagia for solids/liquids and bland 
regurgitation. The diagnosis is suggested by barium esophagram and confirmed by esophageal manometry. Achalasia cannot 
be cured. Instead, our goal is to relieve symptoms, improve esophageal emptying and prevent the development of megaeso-
phagus. The most successful therapies are pneumatic dilation and surgical myotomy. The overall success rate of graded pneu-
matic dilation is 78%, with women and older patients responding best. Laparoscopic myotomy, usually combined with a parti-
al fundoplication, has an overall success rate of 87%. Young patients, especially men, are the best candidates for surgical 
myotomy. Botulinum toxin injection into the lower esophageal sphincter and smooth muscle relaxants are usually reserved for 
older patients or those with co-morbid illness. The prognosis for achalasia patients to return to near normal swallowing is 
good, but the disease is rarely “cured” with a single procedure and intermittent touch-up procedures may be required.
(J Neurogastroenterol Motil 2010;16:232-242)
Key Words
Achalasia; Balloon dilation; Esophageal sphincter lower; Muscle, smooth; Botulinum toxin 
Received: April 29, 2010 Revised: May 25, 2010 Accepted: May 26, 2010
CC This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons. 
org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work 
is properly cited.
*Correspondence: Joel E Richter, MD, FACP, MACG
Department of Medicine, Temple University School of Medicine, 3401 North Broad Street, 801 Parkinson Pavilion, Philadelphia, 
PA 191940, USA
Tel: +1-215-707-5069, Fax: +1-215-707-9004, E-mail: jrichter@temple.edu
Financial support: None.
Conflicts of interest: None.
Introduction
Achalasia is the most recognized motor disorder of the 
esophagus, and is the only primary motility disorder with an es-
tablished pathophysiology. The term means “failure to relax,” 
and describes the primary predominant feature of this disorder, a 
poorly relaxing lower esophageal sphincter (LES) seen in associ-
ation with aperistalsis of the esophageal body. The first case of 
achalasia was reported more than 300 years ago by Thomas 
Willis; where the patient’s cardiospasm responded to dilation 
with a whalebone.
1  
Epidemiology and Pathophysiology
Achalasia occurs with equal frequency in men and women. 
There is no racial predilection. Case studies show an age dis-
tribution between birth and the nineth decade, with the peak in-
cidence between 30 and 60 years of age. In children, it can be part 
of the Triple A syndrome, characterized by achalasia, alacrima 
and adrenocorticotropic hormone resistant adrenal insufficiency. 
Achalasia is an uncommon disease, but occurs frequently enough 
to be encountered at least yearly by most gastroenterologists.  
Esophageal specialists, both gastroenterologists and surgeons, 
may see 10 or more cases a year.
2 The disease prevalence is ap-Achalasia - An Update
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proximately 10 cases per 100,000 population. Its incidence has 
been fairly stable over the last 50 years at approximately 0.5 cases 
per 100,000 population per year. The overall life expectancy of 
patients with achalasia does not differ from those of the general 
population.
3  
The histologic abnormalities in patients with achalasia have 
been well described at autopsy or from myotomy specimens.
4,5 
The primary region of damage is the esophageal myenteric 
(Auerbach’s) plexus, and includes prominent but patchy in-
flammatory response, consisting of predominantly CD3 and 
CD8 positive cytotoxic T lymphocytes, variable numbers of eosi-
nophils and mast cells, loss of ganglion cells and some degree of 
myenteric neurofibrosis. Early disease has more of an in-
flammatory component, with some of the ganglion cells appear-
ing to be intact, while end stage disease is associated with com-
plete loss of ganglion cells and replacement with myenteric 
fibrosis.
5 Even during the early inflammatory stages of achalasia, 
there is a selective loss of postganglionic inhibitory neurons con-
taining nitric oxide (NO) and vasoactive intestinal polypeptide. 
Since postganglionic excitatory neurons are spared, cholinergic 
stimulation continues unopposed, leading sometimes to high 
resting LES pressure.  The loss of inhibitory input results in ab-
normal and usually incomplete LES relaxation. This occurs for 
all stimuli, including electrical field stimulation of muscle strips 
from achalasia patients, intravenous cholecystokinin, esophageal 
distension, and gastric distension fail to induce transient LES re-
laxation in achalasia patients.
6 Aperistalsis is caused by the loss of 
the latency gradient that permits sequential contractions along the 
esophageal body, a process mediated by NO. 
Although achalasia is the best characterized of the esophageal 
motility disorders, its pathogenesis is still not fully elucidated. 
Available data suggests that hereditary, degenerative, auto-
immune and infectious factors are possible causes - the latter 2 
being the most commonly accepted.
7 The presence of cytotoxic T 
lymphocytes, IgM antibodies and evidence of complement acti-
vation and antibodies against myenteric neurons, especially in pa-
tients with specific HLA genotype (DQA1 × 0103 and DQB1
× 0603 alleles), point toward an autoimmune origin of the myen-
teric ganglionitis.
8 However, some of these antineuronal anti-
bodies may be seen in healthy patients and patients with GERD, 
suggesting they may represent an epiphenomenon, and not a 
causative factor.
9 Although these findings are all very interesting, 
it still remains obscure why only neurons in the esophagus and 
LES are destroyed. Furthermore, the exact stimulus initiating 
this immune response or the antigen targeted remains uni-
dentified. The fact that achalasia is confined to the esophagus and 
LES has led to hypotheses that neurotropic viruses, especially vi-
ruses with predilection for squamous epithelium, may be 
involved. However, studies focusing on the presence of viral anti-
bodies in the serum or viral DNA in esophageal tissue show con-
flicting results.
10,11 On the other hand, a recent study suggests a 
causal role for a subpopulation of cytotoxic lymphocytes activated 
by the herpes simplex virus antigens or antigens on neurons sim-
ilar to herpes simplex virus.
12  
Clinical Presentation
The diagnosis of achalasia should be suspected in any pa-
tients complaining of dysphagia for solids and liquids with regur-
gitation of bland food and saliva. The onset of the dysphagia is 
usually gradual, being described initially as an infrequent “full-
ness in the chest” or “sticking sensation,” but usually occurs daily 
or with every meal by the time the patient sees a physician. 
Initially, the dysphagia may be primarily for solids; however, by 
the time of clinical presentation, nearly all complain of dysphagia 
for solids and liquids while eating and drinking, especially cold 
beverages. Various maneuvers, including “power swallows” and 
carbonated beverages, both of which increase intraesophageal 
pressure, may be used to improve esophageal emptying. Regurgi-
tation becomes a problem with progression of the disease, espe-
cially when the esophagus becomes dilated. Regurgitation of 
bland, undigested retained foods or accumulated saliva, some-
times misdiagnosed as postnasal phlegm or bronchitis, occur 
postprandially and at night, often waking the patient from sleep 
because of coughing and choking. Rarely, aspiration pneumonia 
is a problem. Chest pain occurs in some patients, primarily at 
night, and is especially seen in patients with milder disease when 
the esophagus is minimally dilated. The mechanism of chest pain 
is unknown, but it is not simply repetitive episodes of simulta-
neous contractions, causing the esophageal lumen to be occluded. 
Whereas pneumatic dilation or surgery usually relieves dysphagia 
and regurgitation, the chest pain in achalasia patients responds 
much less predictably. Fortunately, the chest pain seems to get 
better over time, possibly as the esophagus dilates.
13 Heartburn is 
a frequent complaint in achalasia, despite the fact that achalasia is 
not associated with increased episodes of acid reflux by pH 
monitoring. The cause of this symptom is speculative, but prob-
ably related to retention of acid beverages such as carbonated or 
fruit drinks and, in some cases, the production of lactic acid from 
retained food in a markedly dilated esophagus. Most achalasia Joel E Richter
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patients have some degree of weight loss at presentation; how-
ever, the loss is usually only 5 to 20 lb over months to years. 
Diagnostic Evaluation
When achalasia is suspected, a barium esophagram with fluo-
roscopy is the best initial diagnostic test. The esophagus is usually 
dilated and sometimes tortuous, does not empty, and retained 
food and saliva produces an air-fluid level at the top of the barium 
column. The distal esophagus is characterized by a smooth taper-
ing from the closed LES, resembling a bird’s beak, and some-
times an epiphrenic diverticulum is noted. Fluoroscopy always 
shows a lack of peristalsis, replaced by to-and-fro movement in 
the supine position. We have popularized a modification of the 
barium esophagram known as the timed barium swallow.
14 The 
test is individualized for each patient and primarily assesses 
esophageal emptying of barium in the upright position over 5 
minutes. Tests can be repeated serially after therapy to evaluate 
esophageal emptying and correlate it with the patients’ symptoms.
Esophageal manometry is required to establish the diagnosis 
of achalasia and must be done in any patient where invasive treat-
ments such as pneumatic dilation or surgical myotomy are 
planned. Because achalasia only involves the smooth muscles of 
the esophagus, the manometry abnormalities are confined to the 
Figure 1. Achalasia subtypes by high resolution manometry. (A) 
Type I (classic achalasia) - there is no significant pressurization within 
the esophageal body (all dark blue) and impaired lower esophageal 
sphincter (LES) relaxation (IRP = 42 mmHg). (B) Type II (acha-
lasia with compression) - water swallows cause rapid pan-esophageal 
pressurization which may exceed LES pressure, causing the eso-
phagus to empty. (C) Type III (spastic achalasia) - although this is also 
associated with rapidly propagated pressurization, the pressurization is 
attributable to an abnormal lumen obliterating contraction. (Modified 
from: Pandolfino JE, Fox MR, Bredenoord AJ, Kahrilas PJ. High 
resolution manometry in clinical practice: utilizing pressure topo-
graphy to classify oeosophageal motility abnormalities. Neurogas-
troenterol Motil 2009;21:796-806). UES, upper esophageal sphinc-
ter; IRP, integrated relaxation pressure; CFV, contractile front 
velocity. Achalasia - An Update
235 Vol. 16, No. 3 July, 2010 (232-242)
distal two-thirds of the esophagus. All patients have at least 2 
pathognomonic abnormalities: aperistalsis and abnormal LES 
relaxation. The aperistalsis is usually characterized by low ampli-
tude, simultaneous mirror image (isobaric) waves, due to a com-
mon cavity phenomenon. Physiologically, the low amplitude 
waves (usually < 30 mmHg) represent simultaneous fluid move-
ment in a fluid filled dilated esophagus, rather than true lumen 
occluding contractions. When pressure waves have a higher am-
plitude and different morphology, indicating active contractions 
of the esophageal body, it is called “vigorous” achalasia. Abnor-
mal LES relaxation is seen in all achalasia patients; about 
70%-80% have absent or incomplete LES relaxation with wet 
swallows, while the remainder will have complete but shortened 
LES relaxation (< 6 seconds). LES resting pressure may be ele-
vated in approximately 50% of patients with achalasia. Some-
times, an increase in the esophageal baseline greater than gastric 
baseline is seen due to retention of food and saliva.
The recent introduction of high resolution manometry has 
greatly helped in making the diagnosis of achalasia.
15,16 It allows a 
more careful evaluation of LES and esophagogastric junction re-
laxation using the integrated relaxation pressure. As reported by 
the Northwestern group in a series of achalasia patients,
15 the tra-
ditional LES nadir pressure had a false negative rate of 48%, 
while an integrated relaxation pressure < 15 mmHg was seen in 
all but 3% of achalasia patients.  The group also described 3 pat-
terns of achalasia: Type I - impaired relaxation with esophageal 
dilation and negligible esophageal pressurization; Type II - 
pan-esophageal pressurization and Type III - spastic contractions 
of the distal esophageal segment (Fig. 1).
16
Pseudoachalasia is a clinical syndrome similar to achalasia, 
being seen in approximately 2%-4% of patients suspected with 
achalasia.
17 In general, patients with pseudoachalasia are older 
and have a shorter history of dysphagia and marked weight loss.  
However, this triad tends to have poor specificity.
18 The most 
common cause of pseudoachalasia is a malignancy infiltrating the 
gastroesophageal junction. Therefore, all patients with suspected 
achalasia need a careful upper endoscopy with close examination 
of the cardia and gastroesophageal junction. If pseudoachalasia is 
still suspected, endoscopic ultrasound with a small 20 mHz probe 
or computed tomography scanning of the chest may be helpful.
Although the symptoms of achalasia are relatively classic, and 
the diagnostic tests, especially barium X-rays and manometry, 
readily available, there is still a considerable delay between the on-
set of symptoms and the diagnosis. In one report, patients on 
average reported symptoms of dysphagia for approximately 5 
years and had seen several physicians before the correct diagnosis 
was made. Interestingly, the frequent delay in the diagnosis was 
not due to an atypical clinical presentation of the disease, but rath-
er to misinterpretation of typical findings by the physician 
consulted.
19  
Treatment of Achalasia
No treatment can restore muscular activity to the denervated 
esophagus in achalasia. Esophageal aperistalsis and impaired 
LES relaxation are rarely, if ever, reversed by any mode of 
therapy. Therefore, every treatment for achalasia is directed to re-
ducing the pressure gradient across the LES with 3 goals of: (1) 
relieving patients’ symptoms, especially dysphagia and bland re-
gurgitation, (2) improving esophageal emptying by disrupting 
the poorly relaxing LES and (3) preventing the development of 
megaesophagus. 
The disruption of the LES gradient is best accomplished by 
pneumatic dilation or surgical myotomy and, less effectively, by 
pharmacologic agents. The symptoms of regurgitation and dys-
phagia are the easiest to treat, but chest pain can be problematic in 
some patients.
13 Overall, using single or multiple modalities of 
treatment, over 90% of achalasia patients will do well.
20 However, 
achalasia is never “cured” and touch-up therapies after pneumatic 
dilation or Heller myotomies are often needed. Therefore, I rec-
ommend that all achalasia patients be followed up every 1 to 2 
years by a gastroenterologist or surgeon familiar with the disease. 
In my experience, the timed barium swallow is very helpful in fol-
lowing these patients,
21 however, my colleagues in Europe prefer 
to do serial measurements of LES pressure.
22,23 
Pneumatic Dilation
Pneumatic dilation aims at disrupting the LES by forceful 
dilation using air filled balloons. This procedure has become eas-
ier and more standardized with the development of the Rigiflex 
balloon system (Boston Scientific Corporation, MA, USA). 
These are noncompliant polyethylene balloons available in 3 di-
ameters (3.0, 3.5 and 4.0 cm), on a flexible catheter that can be 
placed over a guidewire at endoscopy. The catheter within the 
balloon has radiopaque markers which can help identify its loca-
tion at fluoroscopy. Briefly, the procedure is done at the time of 
endoscopy, with the balloon placed over the guidewire and posi-
tioned across the LES. This position is confirmed either by fluo-
roscopy or endoscopy. The balloon is then gradually inflated until Joel E Richter
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Table 2. Pneumatic Dilation: Predictors of Relapse
Related to patient
Younger age (< 40 yr)
Male gender
Wide esophagus
Related to procedure
Single dilation
Small size balloon (< 30 mm)
LES pressure > 10-15 mmHg measured within 1 yr of procedure
Poor esophageal emptying on barium swallow post-treatment
Related to manometry
Type I and III pattern on high resolution manometry
Table 1. Long-term Efficacy and Complications of Rigiflex 
Balloon Dilation Versus Heller Myotomy for Achalasia
Rigiflex Laparoscopic 
balloon myotomy
a
Number of studies      24      30
Number of patients       1,144       1,487
Excellent/good symptom       78.0      86.7
  response (%)
Follow up (months)      37      32
Complications (%)        1.9      18.0 
         (perforation)         (gastroesophageal 
       reflux)
aSurgical series with over 10 patients.
the waist, caused by the spastic LES, is flattened or effaced. The 
pressure required is usually 7-12 psi of air, held for 15-60 
seconds. Sometimes multiple balloon distensions are done at the 
same setting. Some investigators only perform one dilation,
22 but 
most use a graded dilation protocol starting with 3.0 cm, followed 
by 3.5 cm and then 4.0 cm balloon dilation, in subsequent 
sessions.
24 A few European centers perform serial progressive di-
lations over several days, until the manometrically measured LES 
pressure is below 10-15 mmHg.
22,23 Pneumatic dilation is now 
routinely done in outpatient centers, with the patient being ob-
served for up to 6 hours, to ensure that no complications have 
occurred. Some perform Gastrografin followed by barium swal-
lows to exclude perforations; others do not recommend obtaining 
routine barium X-ray films unless clinically indicated. 
Table 1 summarizes the good to excellent symptom relief 
with the Rigiflex balloons in 1,144 patients.
25 These 24 studies, 
with an average follow-up of 37 months, found that the clinical 
response improves in a graded fashion with increasing size of the 
balloon diameter - good to excellent response in 74%, 86% and 
90% with the 3.0, 3.5 and 4.0 balloons, respectively. Over a third 
of achalasia patients treated with pneumatic dilation will experi-
ence symptom recurrence during a 4 to 6-year period of fol-
low-up. Long-term remission can be achieved in virtually all of 
these patients treated by repeated pneumatic dilation according to 
an “on demand” strategy, based on symptom recurrence.
26 
Therefore, in clinical practice, pneumatic dilation is a non-surgi-
cal treatment that will require periodic “touch ups” over the life of 
the patient. Pneumatic dilation is the most cost effective method 
for treating achalasia, when compared to Heller myotomy or 
Botox, over a time period of 5 to 10 years.
27,28
With the standardization of the Rigiflex balloons, we are be-
ginning to define the risk factors for relapse after pneumatic dila-
tion (Table 2). These are mainly young age (< 40 years), male 
gender, single dilation with a 3.0 cm balloon, posttreatment LES 
pressure > 10-15 mmHg, and poor esophageal emptying on 
timed barium swallow. The effects of age on the success of pneu-
matic dilation are most reproducible from as far back as 1971, 
even with the older balloons.
29 For example, Eckardt et al,
30 us-
ing a 4 cm Brown-McHardy dilator, demonstrated a 5-year re-
mission rate of 16% for patients younger than 40 years, compared 
to 58% for those older than 40 years. Recent studies suggest 
young men do not do as well as young women with the pneumatic 
dilation. In a study of 126 patients, Ghoshal et al
31 found that 
male gender, but not age, was independently associated with poor 
outcome after dilation. Another large study from the Cleveland 
Clinic (106 patients, 51 women) confirmed the importance of age 
but also found gender to be equally important.
32 Men, up to age 
50 years, did not do well with a single 3.0 cm Rigiflex pneumatic 
dilation. However, only young women (< 35 years of age) did 
poorly with pneumatic dilation, while most older women had sus-
tained relief over at least 5 years with a single pneumatic dilation. 
Physiologic studies can also predict the long-term success 
rate of pneumatic dilation. Eckhardt and colleagues
22 reported 
that all patients with post procedure LES pressure < 10 mmHg 
were in remission after 2 years, compared with 71% for pressures 
between 10-20 mmHg and 23% for pressures over 20 mmHg.
 
More recently, the Leuven group observed that 66% of their pa-
tients with post procedure LES pressure < 15 mmHg were in 
symptomatic remission after an average of 6 years.
23 Using the 
timed barium swallow, we found that patients with complete 
symptom relief, correlating with marked improvement of esoph-
ageal emptying, were more likely to do well at 3 years than those 
with symptom relief, but poor esophageal emptying (82% vs 
10%, respectively).
21 A randomized clinical trial of pneumatic di-
lation versus surgery found that patients with < 50% improve-Achalasia - An Update
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ment in the height of the barium column at 1 minute post treat-
ment had a 40% risk of treatment failure during follow up.
33 
Most recently, the Northwestern group observed that patients 
with Type II achalasia pattern (esophageal pressurization) on 
high resolution manometry were more likely to respond to any 
therapy (Botox 71%, pneumatic dilation 91% and Heller my-
otomy 100%), compared to Type I (56% overall) and Type III 
(29% overall).
16 This was a single center study whose authors are 
enthusiastic about high resolution manometry, therefore, con-
firmation by other centers of excellence are needed.
The only absolute contraindication to pneumatic dilation is 
poor cardiopulmonary status or other comorbid illnesses prevent-
ing surgery, should an esophageal perforation occur. Some have 
suggested that patients with vigorous achalasia, achalasia asso-
ciated with epiphrenic diverticulum or hiatal hernia, malnu-
trition, or more than 1 previous dilation may have an increased 
risk of perforation. However, a retrospective study of 237 pa-
tients found no difference in clinical, endoscopic, manometric or 
radiographic characteristics among 7 who had perforations, com-
pared to the 230 who did not.
34 Pneumatic dilation can be safely 
done after a failed Heller myotomy, although larger diameter bal-
loons are required (I usually start with a 3.5 cm balloon) and the 
success rate is not as good.
35 
The most serious complication from pneumatic dilation is 
esophageal perforation, with an overall rate in experienced hands 
of 1.9% (range 0%-16%).
25 Treatment may be conservative with 
antibiotics and total parenteral nutrition, or surgical repair through 
a thoracotomy may be required. Other minor complications in-
clude chest pain (15% of patients), aspiration pneumonia, hema-
temesis, fever, esophageal mucosal tear and hematoma. Severe 
complications of gastroesophageal reflux disease (esophagitis, 
peptic stricture and Barrett’s esophagus) are rare after pneumatic 
dilation, but 15%-35% of patients have heartburn, responding to 
proton pump inhibitors.
25 
Laparoscopic Heller Myotomy
The first successful surgery for achalasia was performed in 
1913, by the German surgeon Ernest Heller.
36 This surgery con-
sisted of an anterior and posterior (double) lower esophageal my-
otomy through a laparotomy. Subsequently, the operation was 
modified to a single anterior myotomy performed usually through 
a left posterior thoracotomy. This operation was the primary sur-
gical treatment for achalasia, until the mid 1990’s, with reported 
good success rate (60%-94%) but high postoperative morbidity, 
making this treatment much less attractive.
37 This dramatically 
changed with the introduction of the minimally invasive my-
otomy by Pellegrini and coworkers,
38 in 1992. Initially performed 
through the chest, the overall success of the laparoscopic oper-
ation through the abdomen is superior to the thorascopic 
approach. Patients are usually hospitalized for less than 48 hours 
and can return to work within 1 to 2 weeks. Recent improvements 
on the operation have included extending the myotomy 2-3 cm 
onto the proximal stomach to cut the gastric sling fibers, further 
decreasing LES pressure and improving dysphagia.
39 This more 
aggressive myotomy accentuates the risk for postoperative gastro-
esophageal reflux; therefore, the consensus is to add an in-
complete fundoplication, either an anterior Dor or posterior 
Toupet, to prevent this complication.
40 
Table 1 summarizes the good to excellent relief with laparo-
scopic Heller myotomy in nearly 1,500 patients.
25 Younger pa-
tients, especially men and patients with higher LES pressures, 
may benefit most from primary surgery. Importantly, patients 
who fail pneumatic dilation or Botox treatment can be success-
fully treated with surgical myotomy.
32,41 However, repeated 
Botox injections significantly hinder the dissection of the sub-
mucosal plane, leading to mucosal perforations in 7%-15% of 
operations.
25 Although these perforations are usually recognized 
and repaired at the time of the initial operation, some studies sug-
gest a negative effect on long term results. For example, Portale 
et al
41 found the myotomy success rate of 19 patients previously 
treated with pneumatic dilation was 94% at 5 years, but only 75% 
for the 26 patients previously treated with Botox. Recurrence of 
dysphagia after a laparoscopic Heller myotomy is usually the re-
sult of an incomplete myotomy, particularly on the gastric side, 
esophageal scarring, obstruction by the fundoplication, mega-
esophagus or complications of severe GERD, including esoph-
agitis or peptic stricture. Surgical expertise is key, with most com-
plications occurring in the first 50 operations.
42 Surgery is the 
most costly treatment for achalasia.
27 However, it may be cost-ef-
fective, but only if its effectiveness reliably lasts at least 10 years.
28
Although the short term results of laparoscopic Heller my-
otomy are excellent, it remains to be seen if the long term results 
are as favorable. Three groups have recently reported the long 
term results of laparoscopic Heller myotomy (mean follow up be-
tween 5.3 and 11.2 years) in 179 patients.
43-45 Deterioration over 
time seems to occur with some striking consistency in these multina-
tional studies; 18% required pneumatic dilation, 5% Botox injection 
and 5%-10% required repeat myotomy or esophagectomy.
Surgical complications of laparoscopic Heller myotomy in-Joel E Richter
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clude death (0.1%) and esophageal perforation (7%-15%).
25 The 
most common long term problem is chronic GERD and its se-
quelae, occurring overall in 18% of patients (range 5%-55%).
25 
Most of these patients have reflux symptoms; some esophagitis, 
and rarely Barrett’s esophagus and secondary adenocarcinoma of 
the esophagus have been reported after Heller myotomy. The ad-
dition of an incomplete fundoplication decreases, but does not 
eliminate, the complications of GERD.
40 A recent study by 
Csendes et al,
46 illustrates the potential for GERD complications, 
especially among patients followed for over 10 years. This study 
reported on 67 patients with Heller myotomy and Dor fundopli-
cation after open laparotomy with a mean follow up of nearly 16 
years (range 6.6%-30 years). Overall, 31% of the patients devel-
oped GERD, and 55% had abnormal pH studies 20 years after 
their myotomy. Importantly, 9 patients (13%) developed Barrett’s 
esophagus (6 short segment and 3 long segment), with the fre-
quency increasing over time, reaching 30% after 20 years. In this 
series, poor or failed results were seen in 22.4% of the patients, 
but only 1 was due to an incomplete myotomy, with the remaining 
14 due to complications of severe GERD. These alarming results 
may not be translatable to the laparoscopic operation, where the 
minor dissection of the perihiatal tissue theoretically should re-
duce the risk of postoperative GERD. However, careful studies 
will be required to address this concern.
Pneumatic Dilation or
  Surgical Myotomy?
 Ideally, the choice between 2 treatment options should be 
based upon prospective, randomized comparative studies. Studies 
comparing pneumatic dilation with the Rigiflex balloon and lapa-
roscopic Heller myotomy have recently been reported. These 
studies are appearing at a critical time, when many gastro-
enterologists have stopped performing pneumatic dilations and 
the laparoscopic technique has made Heller myotomy the most 
favored treatment for achalasia. 
A large study from the Cleveland Clinic compared 106 pa-
tients treated with Rigiflex balloons by a single gastroentero-
logist, and 73 undergoing primarily laparoscopic Heller my-
otomy (20 had failed pneumatic dilation and crossed over to sur-
gery) by a single esophageal surgeon.
32 The success of graded 
pneumatic dilation and myotomy, defined as dysphagia/regur-
gitation < 3 times a week or freedom from alternative treatment, 
was similar; 96% versus 89% at 6 months, decreasing to 44% ver-
sus 57% at 6 years. Causes of symptom recurrence were in-
completely treated achalasia (96% after pneumatic dilation vs 
64% after myotomy) and complications of GERD (4% after dila-
tion vs 36% after surgery). 
To date, 2 small randomized studies have been reported 
comparing Rigiflex balloon dilation and laparoscopic myotomy. 
The first (16 pneumatic dilation, 14 Heller myotomy) found no 
difference in success rates.
47 The second series (26 dilations, 25 
surgery) with follow up for at least 12 months, observed 6 failures 
in the dilation group and 1 with surgery. This difference reached 
statistical significance (p = 0.04) in the per protocol analysis, but 
not the intention-to-treat analysis (p = 0.09).
48 Most recently, an 
achalasia trial involving 5 European countries randomized 94 pa-
tients to Rigiflex pneumatic dilation (3.0 and 3.5 cm) and 106 to 
laparoscopic Heller myotomy with Dor fundoplication.
49 After 2 
years of follow up, both treatments had comparable success rates - 
92% for pneumatic dilation and 87% for laparoscopic myotomy. 
Barium swallow emptying and LES pressures were similar for 
both groups. Four perforations occurred after pneumatic dila-
tions, compared to 11 perioperatively recognized perforations (1 
converted to open operation) during laparoscopic Heller myo-
tomy. 
Another method to address this issue is to investigate large 
population based databases comparing outcomes of these 2 pro-
cedures in typical practice settings. This was recently reported by 
Lopushinsky and Urbach
50 in a retrospective longitudinal study 
in Ontario, Canada, from July 1991 to December 2002. A total of 
1,461 persons aged 18 years or older received treatment for acha-
lasia; 1,181 (80.8%) had pneumatic dilation and 280 (19.2%) 
had surgical myotomy as their first procedure. The cumulative 
risk of any subsequent intervention for achalasia (pneumatic dila-
tion, myotomy or esophagectomy) after 1, 5 and 10 years re-
spectively was 36.8%, 56.2% and 63.5% after initial pneumatic 
dilation treatment, as compared to 16.4%, 30.3% and 37.5% after 
initial myotomy (hazard risk, 2.37; CI, 1.86-3.02; p < 0.001). 
The difference in risk between these 2 procedures was observed 
only when repeat pneumatic dilation was recorded as an adverse 
outcome. Since “on demand” pneumatic dilation is the accepted 
approach to treating achalasia, this cannot logically be viewed as 
failure of this treatment modality. Interestingly, the 33% need for 
subsequent pneumatic dilation and 18% risk of repeat surgery 
following myotomy were much higher than the current surgery 
literature suggests, probably defining the more realistic surgical 
experience in the clinical community.Achalasia - An Update
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Figure 2. Suggested algorithm for the 
treatment of achalasia. Healthy patients 
with low risk of complications after 
surgery can be offered potentially defi-
nitive therapy with either pneumatic 
dilation or laparoscopic myotomy. Failu-
res are best referred to Esophageal 
Centers of Excellence with expertise in 
pneumatic dilation, repeat myotomy, 
and esophagectomy. High risk patients, 
especially the elderly, are best treated 
with botulinum toxin injections. (Up-
dated from the American College of 
Gastroenterology Practice Guidelines: 
Diagnosis and management of achala-
sia. American College of Gastroente-
rology Practice Parameter Committee. 
1999;94:3406-3412, with permission).
Pharmacologic Treatments
1. Smooth muscle relaxants
LES pressure can be transiently reduced by smooth muscle 
relaxants.
51 Nitrates increase the NO concentration in smooth 
muscle cells, which subsequently increases cyclic guanosine 
monophosphate levels and results in muscle relaxation. Calcium 
is necessary for esophageal muscle contractions and its action is 
blocked by calcium antagonists. Nitrates and calcium channel 
blockers decrease LES pressure in a dose-dependent manner, 
with a maximum effect of approximately 50%, thereby tempora-
rily relieving dysphagia. These drugs are taken 15-30 minutes 
before meals, the improvement in dysphagia is usually incomplete 
and short lived, efficacy decreases with time, and side effects 
(headache, dizziness and pedal edema) are common. As a result, 
there is infrequently a place for these drugs in the clinical man-
agement of achalasia. The same holds true for sildenafil, a phos-
phodiesterase inhibitor that reduces the breakdown of cyclic gua-
nosine monophosphate, the second messenger mediating NO in-
duced relaxation.
52  
2. Botulinum toxin
Botulinum toxin (Botox) is a potent inhibitor of acetylcholine 
release from nerve endings.
51 The inactive form is synthesized by 
the Clostridium botulinum bacteria. Botox cleaves SNAP-25, a cy-
toplasmic protein involved in the fusion of acetylcholine contain-
ing presymptomatic vesicles with the neuronal plasma mem-
brane. Exocytosis of acetylcholine is inhibited and paralysis of the 
innervated muscle occurs. Botox counteracts the unopposed 
stimulation of the LES by cholinergic neurons, helping to restore 
the LES to a lower resting pressure. On average, Botox injections 
decrease LES pressure by 50%, while partially improving esoph-
ageal emptying.
51
Botox is commercially available in a lyophilized powder 
which should be stored below -5
oC. The toxin is gently diluted 
with 5 mL of preservative-free sterile saline.  Bubbles should not 
be formed during the mixing process, so as not to decrease the 
toxin’s potency. Total dose of 100 units is endoscopically injected 
through a sclerotherapy needle into the LES in divided 25 unit 
aliquots, one in each quadrant of the sphincter.  Increasing the 
dose to 200 units does not improve the success rate, but repeated 
100 units may improve efficacy. One study reported that patients 
receiving 100 units of Botox, followed by a second injection of 
100 units 30 days later, had an 80% remission rate at 12 months, 
compared with the 55% rate with the traditional regimen.
53 The 
drug is contraindicated in patients with allergy to egg proteins. It 
should be administered cautiously to patients receiving amino-
glycosides, because these medications may potentiate the effect of 
the toxin. The most common side effects of Botox injection is 
chest pain in 16%-25% of patients.
Based on numerous studies, some placebo-controlled, Botox 
markedly improves symptoms in approximately 75% of achalasia 
patients.
25 However, symptoms recur in more than 50% of pa-
tients within 6 months, possibly because of regeneration of the af-
fected receptors.
53-55 Of course, those responding to the first in-
jection of 100 units of Botox, nearly 75% will respond to a second Joel E Richter
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injection, but the response decreases with further injections, 
probably from antibody production to the foreign proteins. Less 
than 20% of the patients failing to respond to the initial Botox in-
jection respond to a second injection.
56 Patients older than 60 
years of age, and those with vigorous achalasia, are more likely to 
get a sustained response, up to 1.5 to 2 years to Botox injection.
54 
Serial injections of Botox are required to give sustained relief, and 
comparison studies demonstrate its long term efficacy is inferior 
to pneumatic dilation or myotomy.
55,57 A single vial of Botox costs 
approximately $500. Serial Botox injections are more expensive 
than pneumatic dilation, because of the need for repeated 
injections. This treatment may have a cost advantage for patients 
living < 2 years.
58  
General Recommendations
For the newly diagnosed patient with achalasia, a suggested 
treatment algorithm
59 is shown in Figure 2. Symptomatic healthy 
patients with achalasia should be given the option of graded 
pneumatic dilation or laparoscopic Heller myotomy since a re-
view of the literature suggests relatively similar efficacy in the 
hands of experienced gastroenterologists and surgeons.
25 Pneu-
matic dilation has the advantage of being an outpatient proce-
dure, the pain is minimal, GERD is an infrequent problem, 
pneumatic dilation can be performed in any age group and dur-
ing pregnancy. Pneumatic dilation does not hinder the perform-
ance of a future myotomy, and all cost analyses find it less ex-
pensive than Heller myotomy over 5 to 10 years. On the other 
hand, laparoscopic Heller myotomy has the advantage of being a 
single procedure, the dysphagia relief may be greater at the cost of 
more troubling heartburn, and a myotomy may be more effective 
treatment than pneumatic dilation in adolescents and young 
adults, especially men. Myotomy is definitely the treatment of 
choice in uncooperative patients and patients in whom pseu-
doachalasia cannot be excluded. In healthy subjects, we do not of-
fer Botox as an option, because the treatment is not definitive, and 
the duration of relief short term. On the other hand, Botox in-
jections are the treatment of choice in patients who are poor surgi-
cal candidates and the elderly because it is safe, improves symp-
toms and generally older patients require retreatment no more 
frequently than once a year. Initial treatment of uncomplicated 
achalasia probably can be handled by experienced community 
physicians and surgeons. Failures, particularly after surgery, 
should be referred to Esophageal Centers of Excellence with ex-
pertise in pneumatic dilation, repeat myotomy and esophagec-
tomy. Using this multidiscipline approach, we have found that 
over 90% of achalasia patients can have long term relief or im-
provement in their dysphagia and good quality of life.
20 However, 
few patients are “cured” with a single procedure and intermittent 
“touch up” procedures (especially pneumatic dilation and some-
times repeat myotomy) may be required.  
Conclusion
There are still many challenges and questions to be answered 
regarding achalasia and its treatment. We need to understand the 
triggers leading to the destruction of the esophageal and LES 
neurons and possibly how to prevent these insults. If this is due to 
an autoimmune process, one possible alternative therapeutic ap-
proach may be immune modulating drugs. Animal studies 
should continue to explore the potential of stem cell trans-
plantation to restore esophageal and LES function. Recent stud-
ies of mice suggest that transplantation of neuronal stem cells in-
jected in the pylorus survive and even express NO synthase.
60 
Future large, randomized, prospective trials will need to compare 
laparoscopic Heller myotomy and pneumatic dilation to address 
the superiority of one technique to the other over a 5 to 10 year 
period, or to determine which therapies should be reserved for a 
certain subset of patients.  Initial trials should be done in Centers 
of Excellence with surgeons and gastroenterologists skilled with 
this disease, but a later comparative study in the community set-
ting would best define where these patients should be initially 
treated. Finally, some endoscopic enthusiasts will see if a success-
ful myotomy can be performed through the endoscope. 
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